Empty follicular syndrome mutation site and application thereof

By identifying two new pathogenic sites of the ZP1 gene, detection reagents and kits for vacuolar follicle syndrome are provided, which solves the problem of diagnosing vacuolar follicle syndrome in the prior art and improves diagnostic accuracy and personalization The possibility of treatment reduces the cost of assisted reproductive pregnancy.

CN118910243APending Publication Date: 2024-11-08SHANGHAI FIRST MATERNITY & INFANT HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310278461.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-03-21
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to effectively diagnose and identify the ZP1 gene mutation that causes vacuolar follicle syndrome, leading to assisted reproductive failure and the occurrence of related reproductive diseases, affecting the health and economic costs of patients.

Method used

Two new ZP1 gene pathogenic sites and their associated detection reagents and kits are provided for specific detection of mutations in subjects' genomic DNA, including primers, probes, antibodies and nucleic acid chips, for diagnosis. Vacuum follicle syndrome improves diagnosis accuracy.

Benefits of technology

By identifying the new ZP1 gene mutation site, a diagnostic kit for vacuolar follicle syndrome is provided, which improves the accuracy of clinical diagnosis, provides patients with a theoretical basis for personalized treatment and clinical genetic consultation, and reduces assisted reproductive pregnancy cost.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910243A_ABST
    Figure CN118910243A_ABST
Patent Text Reader

Abstract

The invention relates to a pathogenic mutation site of an empty follicular syndrome and an application of the pathogenic mutation site. The new pathogenic mutation related to the empty follicular syndrome, including c.809Ggt of the ZPI gene, is successfully identified on the basis of clinical resources, by means of a sequencing technology and in combination with clinical manifestations; a (p.C270Y) and c.874Cgt are selected from the group consisting of: A ( T (p.Q292 *) mutation is carried out. The invention provides a new molecular biology basis for diagnosis and risk assessment of the empty follicular syndrome, and is beneficial to improving the accuracy of clinical diagnosis and early diagnosis and treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of disease diagnosis and gene detection, in particular to empty follicle syndrome mutation sites and applications thereof. Background Art

[0002] Empty follicle syndrome (EFS) refers to the inability to retrieve oocytes even after repeated flushing when estradiol (E2) levels are normal and follicle development is normal. EFS can be divided into true and false. False EFS is mainly due to errors in HCG administration or bioavailability, which makes it impossible to retrieve oocytes with low HCG. True EFS is considered to be the failure to retrieve oocytes even when the optimal HCG level is reached on the day of oocyte retrieval. This is due to oocyte maturation disorders caused by follicular dysfunction, ovarian aging or genetic defects.

[0003] Genetic factors are one of the main causes of true EFS. Currently, there are four known pathogenic genes associated with EFS, namely the luteinizing hormone / chorionic gonadotropin receptor gene (LHCGR) and zona pellucida protein encoding genes 1 / 2 / 3 (ZP1 / 2 / 3). Its inheritance patterns include autosomal recessive inheritance and autosomal dominant inheritance. Among them, the empty follicle syndrome caused by the ZP1 gene mutation that has been discovered so far is caused by an autosomal recessive inheritance pattern, and the mutation forms include single nucleotide variation, insertion, and deletion mutations. ZP1 gene mutations can lead to the absence or loss of function of the zona pellucida glycoprotein ZP1 it encodes, resulting in abnormal assembly with other zona pellucida glycoproteins ZP2, ZP3, and ZP4, causing abnormal formation of the zona pellucida in oocytes and oocyte development disorders, ultimately leading to the occurrence of EFS.

[0004] According to statistics, the incidence of EFS in patients undergoing egg retrieval is 0.045%-7%. The occurrence of EFS will lead to repeated assisted reproductive (ART) pregnancy failures in patients, greatly increasing the economic cost of ART pregnancy for patients. In addition, repeated ART pregnancy failures will lead to infertility, seriously affecting the happiness of patients' families, and indirectly affecting the country's newborn birth rate, accelerating the process of social aging, and challenging the country's economic development. Therefore, finding the pathogenic genes and pathogenic mutations of EFS and improving the diagnosis rate of EFS are of great significance for reducing patients' ART pregnancy costs, promoting patients' family harmony, and improving the healthy development of the social population. At the same time, it will also provide a theoretical basis for clinical genetic counseling, precise diagnosis and personalized treatment for similar patients. At present, a study (Wang Liting, Wang Chengxiang, Sun Hongliang, et al. LHCGR gene mutation detection and pedigree analysis of families with empty follicle syndrome [J]. Journal of Binzhou Medical College, 2020, 43(01): 34-37) found that through gene sequencing, an infertile patient with EFS was subjected to LHCGR gene mutation and family analysis. The patient had a homozygous mutation in exon 11 of the LHCGR gene: chr2:48915113A>G, c.1823T>C, p.Leu608Pro. The mutation caused the LHCGR protein to mutate from leucine (Leucine, Leu) to proline (Proline, Pro) at position 608, indicating that LHCGR gene mutations can lead to EFS, and then lead to the occurrence of related reproductive diseases. There are also documents (Dai C, Chen Y, Hu L, et al. ZP1 mutations are associated with empty follicle syndrome: evidence for the existence of an intact oocyte and a zona pellucida in follicles up to the early antral stage. A case report. Hum Reprod, 2019, 34: 2201-2207) and 6 new mutation points on the ZP1 gene were found. It is further speculated that the loss of ZP1 may cause oocytes to become or increase the fragility of oocytes during follicular puncture, ultimately leading to EFS. However, there is no report on the empty follicle syndrome mutation site and its application in this application. Summary of the invention

[0005] The purpose of the present invention is to provide two new pathogenic sites of empty follicle syndrome involving ZP1 gene in view of the deficiencies in the prior art.

[0006] In a first aspect, the present invention provides a reagent for specifically detecting whether any one or both of the following mutations exist in the genomic DNA of a subject:

[0007]

[0008] As a preferred example, the reagent is selected from: one, two or more of a primer, a primer pair, a probe, an antibody and a nucleic acid chip.

[0009] In a second aspect, the present invention provides a kit for diagnosing empty follicle syndrome, wherein the kit contains the reagents as described above.

[0010] In a third aspect, the present invention provides a use of the reagent or kit as described above, wherein the use is selected from:

[0011] 1) Application in the preparation of products for diagnosis or auxiliary diagnosis of empty follicle syndrome;

[0012] 2) Application in the preparation of products for screening or assisting in screening patients with empty follicle syndrome;

[0013] 3) Application in the preparation of products for predicting the risk of empty follicle syndrome;

[0014] 4) Application in the preparation of products for detecting whether genes associated with empty follicle syndrome are mutated;

[0015] 5) Application in the preparation of products for detecting whether proteins associated with empty follicle syndrome are mutated.

[0016] In a fourth aspect, the present invention provides a mutation site combination for detecting empty follicle syndrome, wherein the mutation site combination comprises at least one mutation as described above.

[0017] A fifth aspect provides an application of the above mutation site combination in the preparation of an empty follicle syndrome diagnostic kit.

[0018] In a sixth aspect, the present invention provides a probe composition comprising a probe that specifically binds to a target gene, wherein the probe is capable of detecting at least one mutation as described above.

[0019] As a preferred example, the probe composition is provided in the form of a mixture, or in an independent form.

[0020] In a seventh aspect, the present invention provides a gene capture chip, wherein the probe can detect at least one mutation as described above.

[0021] The present invention has the advantages that:

[0022] The present invention provides two new pathogenic sites of ZP1, which provide a new molecular biological basis for the diagnosis of empty follicle syndrome. A diagnostic kit for empty follicle syndrome can be developed based on the two mutation sites, thereby improving the accuracy of clinical diagnosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Attached Figure 1 The ZP1 mutation carrier status of patients with empty follicle syndrome.

[0024] Attached Figure 2 Shown are the effects of different ZP1 mutations on protein function. DETAILED DESCRIPTION

[0025] Herein, the sequence of the "ZP1" gene refers to the genome sequence (NM_207341.4) provided by the National Center for Biotechnology (NCBI) of the United States.

[0026] The specific embodiments provided by the present invention are described in detail below in conjunction with the accompanying drawings. Unless otherwise specified, the technical means adopted in the embodiments are conventional means well known to those skilled in the art, and the reagents and products used are also commercially available. Various processes and methods not described in detail are conventional methods well known in the art. The sources, trade names and components of the reagents used are indicated when they first appear. If there is no special explanation, the same reagents used in the climate are the same as those indicated for the first time.

[0027] Example 1 Detection of mutation sites in families with primary infertility caused by empty follicle syndrome

[0028] 1 Case data

[0029] Patients with primary infertility due to empty follicle syndrome were recruited from the Shanghai First Maternal and Infant Health Care Hospital. The diagnostic criteria refer to the criteria proposed by Stevenson et al. (Stevenson TL, Lashen H. Empty follicle syndrome: the reality of a controversial syndrome, a systematic review. Fertil Steril. 2008 Sep; 90 (3): 691-8.): In more than two superovulation cycles, follicle development and hormone growth are normal, and the blood human chorionic gonadotropin β subunit (β-HCG) on the day of egg retrieval is normal, but oocytes cannot be obtained after multiple aspiration and flushing of mature follicles. Patients who meet the inclusion criteria participated in this study under the premise of full informed consent, 2 mL of peripheral blood was collected, and an informed consent form was signed. All patients included in the group were excluded from other reproductive endocrine diseases.

[0030] 2 Experimental methods

[0031] 2.1 DNA preparation

[0032] 200 μL of peripheral blood was collected from the patients in the enrolled group, and DNA was extracted according to the instructions of the blood genomic DNA extraction kit (DP348) of Tiangen Company. The concentration and purity of DNA were detected by Thermo Scientific NanoDrop 2000 spectrophotometer. DNA was ultrasonically sheared using Covaris M220 ultrasonic shearing instrument to obtain DNA fragments of 150-200 bp in length; the EndRepair&A-Tailing kit (iGeneTech) was used for end repair; and the IGT TM Adapter & Primer Kit (iGeneTech) was used for connector ligation. TM Pure Beads (iGeneTech) purified and used IGT TM The library was constructed using Fast Library Prep Kit v2.0 (iGeneTech).

[0033] 3 Whole exome sequencing

[0034] Use of constructed DNA library Blocking Oligo(iGeneTech) and TargetSeq Library probe hybridization was performed using Hyb&Wash Kit v2.0 (iGeneTech). Cap Beads (iGeneTech) and Target Probes (iGeneTech) were used to capture the target region, and PostPCR MasterMix (iGeneTech) was used for post-capture PCR amplification. TM After purification with Pure Beads (iGeneTech), high-throughput sequencing was performed on the Illumina Hiseq6000 platform. The sequencing results were quality controlled using FastQC and compared with the human genome reference sequence GRCh37 / hg19 (https: / / www.ncbi.nlm.nih.gov / projects / genome / guide / human / index.shtml), and variant annotation was performed using GATK.

[0035] 4 Filtering strategies

[0036] The annotated data were compared with the gnomAD database to filter out high-frequency mutation sites with a frequency of more than 1 / 100, and synonymous mutations and intronic region mutations were also filtered out. The ZP1 mutations found after screening were verified by PCR combined with Sanger sequencing.

[0037] 5Sanger sequencing verification

[0038] PCR primers (ZP1-Forward: TTTGCAAACTGTGTGCCTTC (SEQ ID NO: 1); ZP1-Reverse: GCTCCTACCTGCATTGTGGT (SEQ ID NO: 2)) were designed for the 200 bp region upstream and downstream of the mutation site. The DNA sample was added to the PCR amplification reaction solution (DNA polymerase, primers, dNTPs, water and buffer) and mixed, and amplified according to the PCR program (denaturation-annealing-extension). The obtained product was purified and further sequenced, and sequenced on an ABI3730 sequencer. The results were analyzed using CodonCodeAligner software.

[0039] 3. Experimental results

[0040] 3.1 Family clinical data

[0041] Two novel mutation sites of the ZP1 gene that have not been reported before were detected in an infertility pedigree from a consanguineous family. The family patient carried a compound heterozygous mutation of ZP1 (c.809G>A and c.874C>T), and his father carried a c.874C>T heterozygous mutation, carrying biallelic mutations. The onset pattern was consistent with the previously reported autosomal recessive inheritance pattern and had typical clinical manifestations; the patient's father only carried a heterozygous mutation and had no related disease manifestations ( Figure 1 ).

[0042] 3.2 Mutations identified by whole exome sequencing

[0043] The c.809G>A mutation is located at position 60637931 of chromosome 11, which will cause the cysteine ​​at position 270 of the encoded protein to change to tyrosine; the c.874C>T mutation is located at position 60638477 of chromosome 11, which will cause the glutamine at position 292 of the encoded protein to change to a stop codon, thereby causing the protein translation to terminate prematurely; (Table 1). The c.809G>A mutation will cause the expression of ZP1 protein to decrease, and the c.874C>T will form an incomplete truncated protein, thereby affecting the normal function of ZP1 protein, and ultimately leading to abnormal oocyte development and EFS occurrence ( Figure 2 ). Therefore, based on the above characteristics, it is confirmed that c.809G>A and c.874C>T mutations are pathogenic mutations.

[0044] Table 1 ZP1 mutation information in patients with empty follicle syndrome

[0045]

[0046] The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention. These improvements and supplements should also be regarded as the scope of protection of the present invention.

Claims

1. A reagent that specifically detects the presence of one or both of the following mutations in the subject's genomic DNA:

2. The reagent according to claim 1, characterized in that The reagent is selected from: one or more of a primer, a primer pair, a probe, an antibody and a nucleic acid chip.

3. A kit for diagnosing empty follicle syndrome, characterized in that: The kit contains the reagent according to claim 1.

4. Use of the reagent according to claim 1 or the kit according to claim 3, characterized in that: The use is selected from: 1) Application in the preparation of products for diagnosis or auxiliary diagnosis of empty follicle syndrome; 2) Application in the preparation of products for screening or assisting in screening patients with empty follicle syndrome; 3) Application in the preparation of products for predicting the risk of empty follicle syndrome; 4) Application in the preparation of products for detecting whether genes associated with empty follicle syndrome are mutated; 5) Application in the preparation of products for detecting whether proteins associated with empty follicle syndrome are mutated.

5. A combination of mutation sites for detecting empty follicle syndrome, characterized in that: The combination of mutation sites comprises at least one mutation described in claim 1.

6. Use of the combination of mutation sites according to claim 5 in preparing a diagnostic kit for empty follicle syndrome.

7. A probe composition comprising a probe that specifically binds to a target gene, characterized in that: The probe is capable of detecting at least one mutation described in claim 1.

8. The probe composition according to claim 7, characterized in that The probe composition is provided in the form of a mixture, or in the form of being independently present.

9. A gene capture chip, comprising a solid phase carrier and a probe array fixed on the solid phase carrier, characterized in that: The probe is capable of detecting at least one mutation described in claim 1.